A Study to Evaluate JYP0061 Tablets in Patients With Moderate-to-severe Atopic Dermatitis

Exclusion Criteria

• •Suspected or confirmed allergy to any component of the study drug or similar ingredients, or having a history of moderate allergic diseases (such as food allergies, drug allergies, etc., except for allergies related to atopic dermatitis) at the time of signing the informed consent form;
• •At the time of screening, having other skin diseases or skin infections that could affect the evaluation of the trial results, or having extensive tattoos, birthmarks, skin scars, etc., in the area of skin lesions, aside from atopic dermatitis;
• •Having or having had other connective tissue diseases, apart from a history of atopic dermatitis;
• •Participation in another clinical trial within one month prior to screening or within five half-lives of the investigational drug (whichever is longer);
• •Underwent major surgery within 12 weeks prior to screening;
• •Conditions that negatively affect the immune response (such as history of organ transplantation), or subjects with known immunodeficiency syndromes (acquired immunodeficiency syndrome, genetic immunodeficiency, and drug-induced immunodeficiency).